Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anzugene autoleucel + mRNA-4203
- Development stage
- Unknown
- Lead developer
- Immatics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
This drug is an experimental combination therapy under investigation for cancer immunotherapy, specifically for previously treated unresectable or metastatic cutaneous melanoma and synovial sarcoma. It combines two components: **anzugene autoleucel (IMA203)**, an autologous T cell receptor (TCR)-engineered T cell therapy targeting the cancer-testis antigen PRAME, and **mRNA-4203**, an mRNA-based therapy encoding the same PRAME antigen designed to boost or support the efficacy of TCR-T cell therapy. The rationale of the combination is to enhance the anti-tumor T cell immune response by simultaneously administering PRAME-specific TCR-T cells and stimulating in vivo immune activation via mRNA vaccination. The drug is being developed in collaboration between Immatics and Moderna and is currently in Phase 1 clinical trials[1][2][3][4][8].
- Brand names
- anzu-cel
- Other names
- ACTengine IMA203 combined with mRNA-4203
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)PRAME (Preferentially expressed antigen in melanoma)
Beyond the preview
Go deeper on anzugene autoleucel + mRNA-4203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anzugene autoleucel + mRNA-4203.